Abstract
Portal vein tumor thrombus(PVTT) is very common in advanced HCC, which plays a major role in the poor prognosis and clinical staging of HCC. Emerging evidence shows that selected patients with PVTT will have better survival and ORR benefit from HAIC versus sorafenib. Oxaliplatin can be used as an inducer of immunogenic cell death(ICD) and as a modulator of the tumor immune microenvironment. Combination therapies composed of oxaliplatin and immune checkpoint inhibitors may open up novel avenues for the treatment of HCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
